The University of Chicago Header Logo

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers.

TKI Type Switching Overcomes ROS1 L2086F in ROS1 Fusion-Positive Cancers. bioRxiv. 2024 Jan 19.

View in: PubMed